• 1
    Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212220.
  • 2
    Lorvick J, Kral AH, Seal KH, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91: 4647.
  • 3
    Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203213.
  • 4
    Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): S11S19.
  • 5
    Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180187.
  • 6
    Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 4246.
  • 7
    Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645653.
  • 8
    Edlin BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy (in press).
  • 9
    Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211214.
  • 10
    Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, Moss AR. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000; 160: 697702.
  • 11
    Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Non-adherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164170.
  • 12
    Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261269.
  • 13
    Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996; 22: 475487.
  • 14
    Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 10991107.
  • 15
    Pilote L, Tulsky JP, Zolopa AR, Hahn JA, Schecter GF, Moss AR. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med 1996; 156: 161165.
  • 16
    Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 117125.
  • 17
    Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected infecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS 2000; 14: 151155.
  • 18
    Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 2001; 27: 251259.
  • 19
    Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357366.
  • 20
    Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29: 824830.
  • 21
    Bamberger JD, Unick J, Klein P, Fraser M, Chesney M, Katz MH. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health 2000; 90: 699701.
  • 22
    Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, Cavalcante S, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 2001; 110: 610615.
  • 23
    Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154: 11211127.
  • 24
    Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, Dewees-Dunk R, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92: 495502.
  • 25
    Mezzelani P, Venturini L, Turrina G, Lugoboni F, Des Jarlais DC. High compliance with a hepatitis B virus vaccination program among intravenous drug users. J Infect Dis 1991; 163: 923.
  • 26
    Marco A, Cayla JA, Serra M, Pedro R, Sanrama C, Guerrero R, Ribot N. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998; 12: 967971.
  • 27
    Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. J Urban Health 1999; 76: 461467.
  • 28
    Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 386390.
  • 29
    Sackett DL, Snow JC: The magnitude of compliance and noncompliance. In: HaynesRB, TaylorDW, SackettDL, eds. Compliance in Health Care. Baltimore: Johns Hopkins University Press, 1979; 1122.
  • 30
    Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 4349.
  • 31
    Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117: 542550.
  • 32
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 2130.
  • 33
    Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, Moss A. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 2001; 26: 435442.
  • 34
    Mushlin AI, Appel FA. Diagnosing potential noncompliance. Physicians' ability in a behavioral dimension of medical care. Arch Intern Med 1977; 137: 318321.
  • 35
    Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 1978; 123: 361370.
  • 36
    Gilbert JR, Evans CE, Hayne RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980; 123: 119122.
  • 37
    Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J 1995; 8: 899904.
  • 38
    Blowey DL, Hebert D, Arbus GS, Pool R, Korus M, Koren G. Compliance with cyclosporine in adolescent renal transplant recipients. Pediatr Nephrol 1997; 11: 547551.
  • 39
    Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep 2002; 51 (RR-7): 155.
  • 40
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188193.
  • 41
    Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117123.
  • 42
    Sylvestre DL: Treatment of HCV in the methadone patient. In: Co-Morbid Conditions Associated With Hepatitis C. Hepatitis Single Topic Conference, Chicago, Illinois, 26–28 April 2002. Alexandria, VA: American Association for the Study of Liver Diseases, 2002; 103107.
  • 43
    Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years' followup. Eur Addict Res 2002; 8: 4549.
  • 44
    National Institutes of Health. Management of hepatitis C [On-line]. (Available: NIH Consens Statement 1997; 15: 141.
  • 45
    O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994; 331: 450459.
  • 46
    Batki S, Sorensen JL: Care of injection drug users with HIV. In: CohenPT, SandeMS, VolderdingPA, eds. The AIDS Knowledge Base: A Textbook on HIV Disease. The University of California, San Francisco and San Francisco General Hospital. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 1999.
  • 47
    Wartenberg AA. HIV disease in the intravenous drug user: role of the primary care physician. J Gen Intern Med 1991; 6 (Suppl 1): S35S40.
  • 48
    Selwyn PA, O'Connor PG. Diagnosis and treatment of substance users with HIV infection. Prim Care 1992; 19: 119156.
  • 49
    Des Jarlais DC, Friedman SR, Ward TP. Harm reduction: a public health response to the AIDS epidemic among injecting drug users. Annu Rev Public Health 1993; 14: 413450.
  • 50
    MarlattGA, ed. Harm reduction: pragmatic strategies for managing highrisk behaviors. New York: Guilford Press, 1998.
  • 51
    Riley D, Sawka E, Conley P, Hewitt D, Mitic W, Poulin C, Room R, et al. Harm reduction: concepts and practice. A policy discussion paper. Subst Use Misuse 1999; 34: 924.
  • 52
    Gostin L. Waging a war on drug users: an alternative public health vision. Law Med Health Care 1990; 18: 385394.
  • 53
    RobertsonR, ed. Management of drug users in the community: a practical handbook. London: Arnold, 1998.
  • 54
    Lowinson JH. Substance abuse: a comprehensive textbook. 3rd ed. Baltimore: Williams & Wilkins, 1997.
  • 55
    StrainEC, StitzerML, eds. Methadone treatment for opioid dependence. Baltimore: Johns Hopkins University Press, 1999.
  • 56
    Gerstein DR, Lewin LS. Treating drug problems. N Engl J Med 1990; 323: 844848.
  • 57
    National Institutes of Health. Effective medical treatment of opiate addiction [On-line]. (Available: NIH Consens Statement 1997; 15: 138.
  • 58
    Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29: 214.
  • 59
    Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep 1998; 113 (Suppl 1): 97106.
  • 60
    Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113 (Suppl 1): 107115.
  • 61
    Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59: 1731.
  • 62
    Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001; 286: 17151723.
  • 63
    Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13 (Suppl 1): S61S72.
  • 64
    Reiter GS, Stewart KE, Wojtusik L, Hewitt R, Segal-Maurer S, Johnson M, Fisher A, et al. Elements of success in HIV clinical care: multiple interventions that promote adherence [On-line]. (Available: = 3098.0093). Top HIV Med 2000; 8: 2130.
  • 65
    Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867876.
  • 66
    Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill JA, Gulati M, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942947.
  • 67
    U. S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins, 1996; 591.
  • 68
    U.S. Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs [On-line]. (Available: ) Rockville, MD: U.S. Public Health Service, 1997.
  • 69
    Rich JD, Macalino GE, McKenzie M, Taylor LE, Burris S. Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001; 91: 699700.
  • 70
    Burris S, Lurie P, Abrahamsson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Ann Intern Med 2000; 133: 218226.
  • 71
    Centers for Disease Control. Fact sheet: physician prescription of sterile syringes to injection drug users [On-line]. (Available: Atlanta, GA: Academy of Educational Development, 2002.
  • 72
    Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271: 115120.
  • 73
    Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992–1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 505511.
  • 74
    Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605611.
  • 75
    NormandJ, VlahovD, MosesL, eds. Preventing HIV transmission: the role of sterile needles and bleach. National Research Council. Institute of Medicine. Washington: National Academy Press, 1995.
  • 76
    National Institutes of Health. Interventions to prevent HIV risk behaviors [On-line]. (Available: NIH Consens Statement 1997; 15: 141.
  • 77
    Edlin BR, Gee L, Kral AH, Seal KH, Lorvick L, Tobler LH, Andrews AA, et al. Decline of hepatitis C virus transmission among injection drug users, San Francisco, 1977–1998 [Abstract 615]. American Association for the Study of Liver Diseases 51st Annual Meeting, Dallas, TX, October 27–31, 2000 (oral presentation). Hepatology 2000; 23: 313A.
  • 78
    Flynn NM, Anderson R, Clancy L, Britton J. Seeing is believing: video-taped high-risk injection behaviour. In: 7th International Conference on the Reduction of Drug Related Harm, Hobart, Australia, March 3–7, 1996.
  • 79
    McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): 2529.
  • 80
    Kral AH, Bluthenthal RH, Erringer EA, Lorvick J, Edlin BR. Risk factors among IDUs who give injections to or receive injections from other drug users. Addiction 1999; 94: 675683.
  • 81
    Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. JAMA 1997; 277: 5362.
  • 82
    Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): S133S138.
  • 83
    Centers for Disease Control. Fact sheet: Policy efforts to increase IDUs' access to sterile syringes [On-line]. (Available: Atlanta, GA: Academy of Educational Development, 2002.
  • 84
    Gleghorn AA, Gee G, Vlahov D. Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): S89S93.
  • 85
    Macalino GE, Springer KW, Rahman ZS, Vlahov D, Jones TS. Community-based programs for safe disposal of used needles and syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1): S111S119.
  • 86
    Centers for Disease Control. Fact sheet: Syringe disposal [On-line]. (Available: Atlanta, GA: Academy of Educational Development, 2002.
  • 87
    Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med (in press).
  • 88
    United Nations General Assembly Resolution 37/194. Principles of Medical Ethics relevant to the Role of Health Personnel, Particularly Physicians, in the Protection of Prisoners and Detainees Against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment. Adopted December 18, 1982.
  • 89
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 18991905.
  • 90
    CDC. Hepatitis C disease burden: estimation method. (Available from: URL: Atlanta: Centers for Disease Control and Prevention, 2002.
  • 91
    Hagan H, Snyder N, Hough E, Yu T, McKiernan S, Boase J, Duchin J. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002; 79 (4): 579585.
  • 92
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450456.
  • 93
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809816.